Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. METHODS: Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day; 3319 patients) or placebo (3313 patients) [correction] in addition to optimal medical therapy. The study continued until 1012 deaths occurred. The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia. RESULTS: During a mean follow-up of 16 months, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008). Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P=0.005). The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02). There was also a reduction in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03). The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001). CONCLUSIONS: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomized controlled trial data regarding in-hospital initiation of MRA therapy among patients with HFrEF is limited to the EPHESUS trial.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [38]
In the citing paper
“Mineralocorticoid receptor antagonists (spironolactone, eplerenone) can also be effective antihypertensive agents (particularly for those with borderline or low potassium levels)89 and are important for morbidity and mortality reduction in patients with left ventricular dysfunction.90,91”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [90]
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Self-citationDickstein, K., & Kjekshus, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09895-1 · Cited by 1,203
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
Aldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
Aldosterone-Induced Inflammation in the Rat Heart
Sun, Y., Zhang, J., Lu, L., Chen, S. S., Quinn, M. T., & Weber, K. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64454-9 · Cited by 567
Farquharson, C. A. J., & Struthers, A. D. (2000) · Circulation · doi:10.1161/01.cir.101.6.594 · Cited by 532
Pitt, B., Williams, G., Remme, W., Martinez, F., Lopez-Sendon, J., Zannad, F., Neaton, J., Roniker, B., Hurley, S., Burns, D., et al. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1011119003788 · Cited by 364
Self-citation
Research works printed but not linked: 3
- Rodriguez JA, 1997, Rev Med Chile, 125, 643
- Schaefer A, 2002, Eur Heart J, 23, 401
- de Gasparo M, 1987, J Pharmacol Exp Ther, 240, 650
Cited by
Items 601–700 of 1,018
Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases
Barrera‐Chimal, J., Bonnard, B., & Jaisser, F. (2022) · Annual Review of Physiology · doi:10.1146/annurev-physiol-060821-013950 · Cited by 106
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 159
Kobayashi, N., Hara, K., Tojo, A., Onozato, M. L., Honda, T., Yoshida, K., Mita, S.-I., Nakano, S., Tsubokou, Y., & Matsuoka, H. (2005) · Hypertension · doi:10.1161/01.hyp.0000157408.43807.5a · Cited by 102
Gueret, A., Harouki, N., Favre, J., Galmiche, G., Nicol, L., Henry, J., Besnier, M., Thuillez, C., Richard, V. J., Kolkhof, P., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06709 · Cited by 102
Packer, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1732 · Cited by 105
Hultman, M. L., Krasnoperova, N. V., Li, S., Du, S., Xia, C., Dietz, J. D., Lala, D. S., Welsch, D. J., & Hu, X. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0537 · Cited by 98
Diuretic usage in heart failure: a continuing conundrum in 2005
Gupta, S., & Neyses, L. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi176 · Cited by 110
C-Reactive Protein Makes Human Endothelium Stiff and Tight
Kusche‐Vihrog, K., Urbanová, K., Blanqué, A., Wilhelmi, M., Schillers, H., Kliche, K., Pavenstädt, H., Brand, E., & Oberleithner, H. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.163444 · Cited by 101
Cardiac Contractility Modulation by Non-Excitatory Currents: Studies in Isolated Cardiac Muscle
Brunckhorst, C., Shemer, I., Mika, Y. H., Ben‐Haim, S. A., & Burkhoff, D. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.05.011 · Cited by 103
Wu, V., Chueh, S., Chang, H., Lin, L., Liu, K., Lin, Y., Ho, Y., Lin, W., Wang, S., Huang, K., et al. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.06.014 · Cited by 103
Hypertension: Pathophysiology and Treatment
Delacroix, S., & Chokka, R. G. (2014) · Journal of Neurology & Neurophysiology · doi:10.4172/2155-9562.1000250 · Cited by 118
Mueller, K. B., Bender, S. B., Hong, K., Yang, Y., Aronovitz, M. A., Jaisser, F., Hill, M. A., & Jaffe, I. Z. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.06172 · Cited by 99
Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure
Tamirisa, K. P., Aaronson, K. D., & Koelling, T. M. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.10.005 · Cited by 99
Shavit, L., Lifschitz, M. D., & Epstein, M. (2012) · Kidney International · doi:10.1038/ki.2011.505 · Cited by 104
The Role of Aldosterone in the Metabolic Syndrome
Briet, M. B., & Schiffrin, E. L. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0182-2 · Cited by 101
Grune, J., Benz, V., Brix, S., Salatzki, J., Blumrich, A., Höft, B., Klopfleisch, R., Foryst-Ludwig, A., Kolkhof, P., & Kintscher, U. (2016) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000366 · Cited by 94
The Biology of Normal Zona Glomerulosa And Aldosterone-Producing Adenoma: Pathological Implications
Seccia, T. M., Caroccia, B., Gómez-Sánchez, E. P., Gómez-Sánchez, C. E., & Rossi, G. P. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00060 · Cited by 120
Novel pharmacotherapies to abrogate postinfarction ventricular remodeling
Dorn, G. W. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.12 · Cited by 112
Is aldosterone bad for the heart?
Funder, J. W. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.03.006 · Cited by 106
Targeting the renin–angiotensin–aldosterone system in heart failure
Lang, C. C., & Struthers, A. D. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.196 · Cited by 101
Fibroblast-mediated pathways in cardiac hypertrophy
Fujiu, K., & Nagai, R. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.01.013 · Cited by 110
Stein, P. K., Sanghavi, D., Domitrovich, P. P., MACKEY, R. A., & DEEDWANIA, P. C. (2008) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2008.01225.x · Cited by 97
Regnault, V., Lagrange, J., Pizard, A., Safar, M. E., Fay, R., Pitt, B., Challande, P., Rossignol, P., Zannad, F. M., & Lacolley, P. J. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.02046 · Cited by 98
Self-citationRahimy, E., Pitcher, J. D., Hsu, J., Adam, M. K., Shahlaee, A., Samara, W. A., VANDER, J. F., Kaiser, R. S., Chiang, A., Spirn, M. J., et al. (2017) · Retina · doi:10.1097/iae.0000000000001649 · Cited by 97
Heart Failure Around the World
Tromp, J., Ferreira, J. P., Janwanishstaporn, S., Shah, M., Greenberg, B., Zannad, F. M., & Lam, C. S. P. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1585 · Cited by 99
Self-citationAhokas, R. A., Sun, Y., Bhattacharya, S. K., Gerling, I. C., & Weber, K. T. (2005) · Circulation · doi:10.1161/01.cir.0000151516.84238.37 · Cited by 94
Adamopoulos, C., Ahmed, A., Fay, R., Angioï, M., Filippatos, G. S., Vincent, J., Pitt, B., Zannad, F. M., & the EPHESUS Investigators (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp136 · Cited by 100
Self-citationLatouche, C., Moghrabi, S. E., Messaoudi, S., Cat, A. N. D., Hernández-Díaz, I., de la Rosa, D. Á., Perret, C., López‐Andrés, N., Rossignol, P., Zannad, F. M., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.187872 · Cited by 97
Self-citationPlasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury
Ma, J., Weisberg, A. D., Griffin, J. P., Vaughan, D. E., Fogo, A. B., & Brown, N. J. (2006) · Kidney International · doi:10.1038/sj.ki.5000201 · Cited by 99
Sugiyama, T., Yoshimoto, T., Tsuchiya, K., Gochou, N., Hirono, Y., Tateno, T., Fukai, N., Shichiri, M., & Hirata, Y. (2005) · Endocrinology · doi:10.1210/en.2004-1674 · Cited by 100
Update in Diuretic Therapy: Clinical Pharmacology
Brater, D. C. (2011) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2011.09.003 · Cited by 95
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy
Heier, C. R., Yu, Q., Fiorillo, A. A., Tully, C., Tucker, A., Mázala, D. A. G., Uaesoontrachoon, K., Srinivassane, S., Damsker, J. M., Hoffman, E. P., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201800186 · Cited by 97
PHARMACOKINETICS AND METABOLISM OF [14C]EPLERENONE AFTER ORAL ADMINISTRATION TO HUMANS
Cook, C. S., Berry, L., Bible, R. H., Hribar, J. D., Hajdu, E., & Liu, N. W. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1448 · Cited by 107
Aldosterone Directly Induces Myocyte Apoptosis Through Calcineurin-Dependent Pathways
Mano, A., Tatsumi, T., Shiraishi, J., Keira, N., Nomura, T., Takeda, M., Nishikawa, S., Yamanaka, S., Matoba, S., Kobara, M., et al. (2004) · Circulation · doi:10.1161/01.cir.0000135599.33787.ca · Cited by 102
RetractedMechanical Device–Based Methods of Managing and Treating Heart Failure
MANCINI, D. M., & Burkhoff, D. (2005) · Circulation · doi:10.1161/circulationaha.104.481259 · Cited by 100
Seeger, F. H., Rasper, T., Fischer, A., Muhly-Reinholz, M., Hergenreider, E., Leistner, D. M., Sommer, K., Manavski, Y., Henschler, R., Chavakis, E., et al. (2012) · Circulation Research · doi:10.1161/circresaha.112.265678 · Cited by 97
Adipocytes, aldosterone and obesity-related hypertension
Dinh Cat, A. N., Friederich-Persson, M., White, A., & Touyz, R. M. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0025 · Cited by 96
Benziger, C. P., do Carmo, G. A. L., & Ribeiro, A. L. P. (2016) · Cardiology Clinics · doi:10.1016/j.ccl.2016.08.013 · Cited by 115
Zhao, J., Li, J., Li, W., Li, Y., Shan, H., Gong, Y., & Yang, B. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00551.x · Cited by 100
Epithelial Sodium Channel Inhibition in Cardiovascular DiseaseA Potential Role for Amiloride
TEIWES, J., & Toto, R. (2006) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2006.05.022 · Cited by 107
Drugs for Left Ventricular Remodeling in Heart Failure
Frigerio, M., & Roubina, E. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.09.060 · Cited by 100
Heart Failure and Diabetes Mellitus: Epidemiology and Management of an Alarming Association
Solal, A. C., Beauvais, F., & Logeart, D. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.04.001 · Cited by 99
Calcium paradox of aldosteronism and the role of the parathyroid glands
Vidal, A., Sun, Y., Bhattacharya, S. K., Ahokas, R. A., Gerling, I. C., & Weber, K. T. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00535.2005 · Cited by 93
Gao, X., Peng, L., Adhikari, C. M., Lin, J., & Zuo, Z. (2007) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.11.015 · Cited by 94
Gustafsson, M., Alehagen, U., & Johansson, P. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.02.004 · Cited by 100
Long-Term Effects of Spironolactone in Peritoneal Dialysis Patients
Ito, Y., Mizuno, M., Suzuki, Y., Tamai, H., Hiramatsu, T., Ohashi, H., Ito, I., Kasuga, H., Horie, M., Maruyama, S., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013030273 · Cited by 101
Newfell, B. G., Iyer, L. K., Mohammad, N. N., McGraw, A. P., Ehsan, A., Rosano, G. M. C., Huang, P. L., Mendelsohn, M. E., & Jaffe, I. Z. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.229070 · Cited by 94
Meyers, M. J., Arhancet, G. B., Hockerman, S. L., Chen, X., Long, S. A., Mahoney, M. W., Rico, J. R., Garland, D. J., Blinn, J. R., Collins, J. T., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100505n · Cited by 97
Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease
Bernardi, S., Michelli, A., Zuolo, G., Candido, R., & Fabris, B. (2016) · Journal of Diabetes Research · doi:10.1155/2016/8917578 · Cited by 104
Aldosterone-receptor antagonism in hypertension
Jansen, P. M., Danser, A. J., Imholz, B. P., & van den Meiracker, A. H. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832810ed · Cited by 90
Progression of Cardiovascular Damage: The Role of Renin–Angiotensin System Blockade
Probstfield, J. L., & O’Brien, K. D. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.006 · Cited by 100
Harjola, V., Parissis, J., Bauersachs, J. K., Rocca, H. B., Bueno, H., Čelutkienė, J., Chioncel, O. D., Coats, A. J. S., Collins, S. P., de Boer, R. A., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1831 · Cited by 105
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome
Harrington, J., Jones, W. S., Udell, J. A., Hannan, K. L., Bhatt, D. L., Anker, S. D., Petrie, M. C., Vedin, O., Butler, J., & Hernandez, A. F. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.02.008 · Cited by 106
Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011): Digest Version
JCS Joint Working Group (2012) · Circulation Journal · doi:10.1253/circj.cj-66-0053 · Cited by 103
Biomarkers to Guide Medical Therapy in Primary Aldosteronism
Hundemer, G. L., Leung, A. A. C., Kline, G. A., Brown, J. M., Turcu, A. F., & Vaidya, A. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad024 · Cited by 97
Pitt, B., Filippatos, G., Gheorghiade, M., Kober, L., Krum, H., Ponikowski, P., Nowack, C., Kolkhof, P., Kim, S.-Y., & Zannad, F. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs061 · Cited by 90
Self-citationPiccini, J. P., White, J. A., Mehta, R. H., Lokhnygina, Y., Al-Khatib, S. M., Tricoci, P., Pollack, C. V., Montalescot, G., Van de Werf, F., Gibson, C. M., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.071860 · Cited by 89
Concomitant Diabetes Mellitus and Heart Failure
Dei, A., Fonarow, G. C., Gheorghiade, M., & Butler, J. (2014) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2014.09.002 · Cited by 94
Lemarié, C. A., Simeone, S., Nikonova, A. S., Ebrahimian, T., Deschênes, M.-E., Coffman, T. M., Paradis, P., & Schiffrin, E. L. (2009) · Circulation Research · doi:10.1161/circresaha.109.196576 · Cited by 92
Aldosterone-Specific Activation of Cardiomyocyte Mineralocorticoid Receptor In Vivo
Messaoudi, S., Gravez, B., Tarjus, A., Pelloux, V., Ouvrard‐Pascaud, A., Delcayre, C., Samuel, J., Launay, J., Sierra‐Ramos, C., de la Rosa, D. Á., et al. (2013) · Hypertension · doi:10.1161/hypertensionaha.112.198986 · Cited by 98
Martínez‐Martínez, E., Buonafine, M., Boukhalfa, I., Ibarrola, J., Fernández‐Celis, A., Kolkhof, P., Rossignol, P., Girerd, N., Mulder, P. G. H., López‐Andrés, N., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09791 · Cited by 92
Matching the Market for Heart Transplantation
Hsich, E. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002679 · Cited by 104
Medical Therapies for Heart Failure With Preserved Ejection Fraction
Kjeldsen, S. E., von Lueder, T. G., Smiseth, O. A., Wachtell, K., Mistry, N., Westheim, A. S., Hopper, I., Julius, S., Pitt, B., Reid, C. M., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.14057 · Cited by 98
Self-citationWaldmann, V., Jouven, X., Narayanan, K., Piot, O., Chugh, S. S., Albert, C. M., & Marijon, É. (2020) · Circulation Research · doi:10.1161/circresaha.120.316756 · Cited by 96
Hill, M. A., Jaisser, F., & Sowers, J. R. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa326 · Cited by 97
Kolkhof, P., Joseph, A., & Kintscher, U. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105859 · Cited by 94
Kazory, A., & Ross, E. A. (2008) · Circulation · doi:10.1161/circulationaha.107.742270 · Cited by 92
Endothelium-Derived Nitric Oxide Modulates Vascular Action of Aldosterone in Renal Arteriole
Arima, S., Kohagura, K., Xu, H.-L., Sugawara, A., Uruno, A., Satoh, F., Takeuchi, K., & Ito, S. (2003) · Hypertension · doi:10.1161/01.hyp.0000111138.78714.1a · Cited by 94
Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African Americans With Heart Failure
McNamara, D. M., Tam, S. W., Sabolinski, M. L., Tobelmann, P., Janosko, K. M., Taylor, A. L., Cohn, J. N., Feldman, A. M., & Worcel, M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.030 · Cited by 94
Eplerenone Inhibits Atherosclerosis in Nonhuman Primates
Takai, S., Jin, D., Muramatsu, M., Kirimura, K., Sakonjo, H., & Miyazaki, M. (2005) · Hypertension · doi:10.1161/01.hyp.0000184640.81730.22 · Cited by 91
Zannad, F. M., & Radauceanu, A. (2005) · Heart Failure Reviews · doi:10.1007/s10741-005-2351-3 · Cited by 91
Self-citationRole of aldosterone and angiotensin II in insulin resistance: an update
Lastra‐Lastra, G., Sowers, J. R., Restrepo‐Erazo, K., Manrique‐Acevedo, C., & Lastra‐González, G. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03498.x · Cited by 90
Shah, A. M., Pfeffer, M. A., Hartley, L. H., Moyé, L. A., Gersh, B. J., Rutherford, J. D., Lamas, G. A., Rouleau, J. L., Braunwald, E., & Solomon, S. D. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.05.021 · Cited by 98
Diuretic Therapy in Heart Failure – Current Approaches
Casu, G., & Merella, P. (2015) · European Cardiology Review · doi:10.15420/ecr.2015.10.01.42 · Cited by 107
Role of Aldosterone and Mineralocorticoid Receptor in Cardiovascular Aging
Gorini, S., Kim, S. K., Infante, M., Mammi, C., Vignera, S. L., Fabbri, A., Jaffe, I. Z., & Caprio, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00584 · Cited by 94
Coactivation of the N-terminal Transactivation of Mineralocorticoid Receptor by Ubc9
Yokota, K., Shibata, H., Kurihara, I., Kobayashi, S., Suda, N., Murai-Takeda, A., Saito, I., Kitagawa, H., Kato, S., Saruta, T., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607741200 · Cited by 85
Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure
Ferreira, J. P., Santos, M., Almeida, S., Marques, I., Bettencourt, P., & Carvalho, H. C. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.08.711 · Cited by 98
Vukadinović, D., Lavall, D., Vukadinović, A. N., Pitt, B., Wagenpfeil, S., & Böhm, M. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.03.011 · Cited by 94
Self-citationPathogenesis of Chronic Cardiorenal Syndrome: Is There a Role for Oxidative Stress?
Rubattu, S., Mennuni, S., Testa, M., Mennuni, M., Pierelli, G., Pagliaro, B., Gabriele, E., Coluccia, R., Autore, C., & Volpe, M. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141123011 · Cited by 88
Diabetes Mellitus and Heart Failure: Epidemiology, Mechanisms, and Pharmacotherapy
Masoudi, F. A., & Inzucchi, S. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.013 · Cited by 97
Spirolactones: Recent Advances in Natural Products, Bioactive Compounds and Synthetic Strategies
Quintavalla, A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666171106162259 · Cited by 89
Rosselló, X., Ariti, C. A., Pocock, S., Ferreira, J. P., Girerd, N., McMurray, J. J. V., van Veldhuisen, D. J., Pitt, B., & Zannad, F. M. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1378-0 · Cited by 94
Self-citationEdelmann, F., Tomaschitz, A., Wachter, R., Gelbrich, G., Knoke, M., Dungen, H.-D., Pilz, S., Binder, L., Stahrenberg, R., Schmidt, A., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr292 · Cited by 90
Galectin-3 and post-myocardial infarction cardiac remodeling
Meijers, W. C., van der Velde, A. R., Pascual-Figal, D. A., & de Boer, R. A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.06.025 · Cited by 95
Aldosterone and Mineralocorticoid Receptors in the Cardiovascular System
Funder, J. W. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.12.003 · Cited by 94
Hypertension management: an update.
Nguyen, Q., Dominguez, J., Nguyen, L. D., & Gullapalli, N. (2010) · Europe PMC (PubMed Central) · Cited by 136
Chan, P. S., Soto, G., Jones, P. G., Nallamothu, B. K., Zhang, Z., Weintraub, W. S., & Spertus, J. A. (2009) · Circulation · doi:10.1161/circulationaha.108.820472 · Cited by 87
Palmer, B. R., Pilbrow, A. P., Frampton, C. M., Yandle, T. G., Skelton, L., Nicholls, M. G., & Richards, M. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn383 · Cited by 88
Differential action of steroid hormones on human endothelium
Oberleithner, H., Riethmüller, C., Ludwig, T. E., Shahin, V., Stock, C. M., Schwab, A., Hausberg, M., Kusche, K., & Schillers, H. (2006) · Journal of Cell Science · doi:10.1242/jcs.02886 · Cited by 95
Collier, T. J., Pocock, S., McMurray, J. J. V., Zannad, F. M., Krum, H., van Veldhuisen, D. J., Swedberg, K. B., Shi, H. H., Vincent, J., & Pitt, B. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht247 · Cited by 88
Self-citationSartório, C. L., Fraccarollo, D., Galuppo, P., Leutke, M., Ertl, G., Stefanon, I., & Bauersachs, J. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.093450 · Cited by 86
Ishizawa, K., Izawa, Y., Ito, H., Miki, C., Miyata, K., Fujita, Y., Kanematsu, Y., Tsuchiya, K., Tamaki, T., Nishiyama, A., et al. (2005) · Hypertension · doi:10.1161/01.hyp.0000172622.51973.f5 · Cited by 86
Bramlage, P., Swift, S. L., Thoenes, M., Minguet, J., Ferrero, C., & Schmieder, R. E. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.444 · Cited by 85
Heart failure in African Americans: Disparities can be overcome
Sharma, A. K., Colvin, M. M., & Yancy, C. W. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13045 · Cited by 95
Ma, T., Wong, I. C. K., Man, K. K. C., Chen, Y., Crake, T., Ozkor, M. A., Ding, L., Wang, Z., Zhang, L., & Wei, L. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210988 · Cited by 108
Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure
Newman, J. D., O’Meara, E., Böhm, M., Savarese, G., Kelly, P. R., Vardeny, O., Allen, L. A., Lancellotti, P., Gottlieb, S. S., Samad, Z. Z., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.033 · Cited by 96
Aldosterone-Induced Organ Damage: Plasma Aldosterone Level and Inappropriate Salt Status
SATO, A., & SARUTA, T. (2004) · Hypertension Research · doi:10.1291/hypres.27.303 · Cited by 86
Zannad, F., McMurray, J. J. V., Drexler, H., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., & Pitt, B. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq049 · Cited by 84
Self-citationNongenomic Effects of Aldosterone in the Human Heart: Interaction With Angiotensin II
Chai, W., Garrelds, I. M., VRIES, R. D., Batenburg, W. W., van Kats, J. P., & Danser, A. H. J. (2005) · Hypertension · doi:10.1161/01.hyp.0000182661.98259.4f · Cited by 100
Cohn, J. N., Anand, I. S., Latini, R., Masson, S., Chiang, Y., & Glazer, R. D. (2003) · Circulation · doi:10.1161/01.cir.0000091234.45664.62 · Cited by 87
Metadata
- Authors
- Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M.
- Affiliations
- University of Michigan (US)
- Cardiovascular Research Foundation (US)
- University of Minnesota (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1309-1321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152094259
- Cited by
- 4,941
- References
- 27
- Citations by year
- 2026: 120 · 2025: 148 · 2024: 136 · 2023: 150 · 2022: 155 · 2021: 156 · 2020: 164 · 2019: 147 · 2018: 187 · 2017: 188 · 2016: 177 · 2015: 224 · 2014: 239 · 2013: 270 · 2012: 281
- FWCI
- 180.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- eplerenone, mineralocorticoid receptor antagonists, left ventricular dysfunction, myocardial infarction, heart failure, cardiovascular mortality, sudden cardiac death, hyperkalemia, hypokalemia, hospitalization, ventricular arrhythmias, mortality reduction, secondary prevention
- MeSH terms
- Eplerenone, Aged, Mineralocorticoid Receptor Antagonists, Blood Pressure, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Myocardial Infarction, Potassium, Spironolactone, Survival Analysis, Death, Sudden, Cardiac, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.